Brand name: Fluoxetine (Generic Health) TM
Active ingredients: fluoxetine
What it is used for
Major depression. Obsessive Compulsive Disorder. Premenstrual Dysphoric Disorder (PMDD) as defined by DSM-IV criteria.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Oral
- Store below 25 degrees Celsius
- Lifetime is 2 Years.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
Light green/off-white size 3 capsule containing white powder
Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.
Is this medicine subsidised?
This medicine is subsidised which may make it cheaper. To learn more about this subsidy, visit the Phamaceutical Benefits Scheme (PBS) website
Pregnant or planning a pregnancy?
For the active ingredient fluoxetine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf)
Need more information?
These trusted information partners have more on this topic.
Top results
Fluoxetine AN Capsules - myDr.com.au
Fluoxetine AN Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Fluoxetine Generichealth Capsules - myDr.com.au
Fluoxetine Generichealth Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Fluoxetine RBX Capsules - myDr.com.au
Fluoxetine RBX Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Fluoxetine-GA Capsules - myDr.com.au
Fluoxetine-GA Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Fluoxetine Sandoz Capsules - myDr.com.au
Fluoxetine Sandoz Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Pharmacor Fluoxetine Capsules - myDr.com.au
Pharmacor Fluoxetine Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Chemmart Fluoxetine Capsules - myDr.com.au
Chemmart Fluoxetine Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
APO-Fluoxetine Capsules - myDr.com.au
APO-Fluoxetine Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Terry White Chemists Fluoxetine Capsules - myDr.com.au
Terry White Chemists Fluoxetine Capsules - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Depression - Orygen, The National Centre of Excellence in Youth Mental Health
Orygen, The National Centre of Excellence in Youth Mental Health is the world’s leading research and knowledge translation organisation focusing on mental ill-health in young people.
Read more on Orygen, The National Centre of Excellence in Youth Mental Health website
Top results
Fluoxetine compared with other antidepressants for depression in adults | Cochrane
Depression is a severe mental illness characterised by a persistent low mood and loss of all interest and pleasure, usually accompanied by a range of symptoms such as appetite change, sleep disturbance and poor concentration. The predominant treatment options for depression are drugs and psychological therapies, but antidepressant drugs are the most common treatment for moderate to severe depression. Fluoxetine, one of the first new generation antidepressants, is an extremely popular drug treatment for depression. However, findings from studies comparing fluoxetine with other antidepressants are controversial. In this systematic review, the efficacy and tolerability of fluoxetine was compared with other antidepressants for the acute treatment of depression.
Read more on Cochrane (Australasian Centre) website
Second-generation antidepressants for winter depression | Cochrane
Seasonal affective disorder (winter depression) is a type of depression that recurs in the autumn and lasts until the spring. It is similar to regular depression except sufferers are usually very tired and have an increase in their appetite. It is more common in countries with few daylight hours in winter. One of the mainstays of treatment for all depression, including winter depression, are second-generation antidepressants (SGAs) such as selective serotonin reuptake inhibitors (SSRIs), and serotonin and norepinephrine reuptake inhibitors (SNRIs). It is not clear how well these drugs work for winter depression and how they compare to each other or to other types of therapy such as light therapy.
Read more on Cochrane (Australasian Centre) website
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus | Cochrane
Obesity is closely related to type 2 diabetes and weight reduction is an important part of the care delivered to obese persons with diabetes. This review of drugs for weight loss among adults with type 2 diabetes revealed weight loss of between 2.0 and 5.1 kg for fluoxetine, orlistat and sibutramine at follow-up of up to 57 weeks. The long-term effects remain uncertain. Adverse events were common in all three drugs: gastrointestinal side effects with orlistat; tremor, somnolence, and sweating with fluoxetine; and palpitations with sibutramine. There were few studies examining other drugs used for weight loss in populations with diabetes.
Read more on Cochrane (Australasian Centre) website
Selective serotonin reuptake inhibitors (SSRIs) for fibromyalgia | Cochrane
Researchers of the Cochrane Collaboration conducted a review of research about the effects of antidepressants classified as serotonin reuptake inhibitors (SSRIs) on fibromyalgia. After searching for all relevant studies up to June 2014, they found seven studies that compared SSRIs with a fake medication. These studies included a total of 383 people. Most participants were middle-aged women. The SSRIs that they studied were citalopram, fluoxetine and paroxetine. Five studies were each funded by pharmaceutical companies, and two studies were funded by public institutions.
Read more on Cochrane (Australasian Centre) website
Use of medication to treat depression in people with opioid dependence | Cochrane
There is little evidence to support the use of antidepressants for treating people who are dependent on opioids and have clinical depression. Depression is more common in people with substance abuse and dependence than in the general population. The depression experienced is also associated with an increased risk of completed suicide. Depression may represent an independent disorder, the psychosocial stress associated with addictive behavior or it could be a consequence of drug use and drug withdrawal effects. A maintenance program with opioid agonists (methadone, buprenorphine, LAAM) is an effective treatment for people who are dependent on opioids in terms of retention in treatment and reduced use of opioids. Depression is however still prevalent and negatively impacts on treatment outcomes. Treatment with antidepressant drugs has therefore been proposed. These adjunct drug treatments include tricyclic antidepressants (doxepin, desipramine, imipramine) and selective serotonin reuptake inhibitors (SSRIs fluoxetine, sertraline).
Read more on Cochrane (Australasian Centre) website
Drugs in breastfeeding | Issue 5 | Volume 38 | Australian Prescriber
Most commonly used drugs are relatively safe for breastfed babies. The dose received via milk is generally small and much less than the known safe doses of...
Read more on Australian Prescriber website
Assessing depressive symptoms in young people - A guide for primary care health professionals
When young people are experiencing distress or depressive symptoms, there may be explanations other than depression, such as grief and loss, trauma or distressing life events, or difficulties in expressing and managing anger, sadness, fear and shame
Read more on beyondblue website
Depression in young people - A desktop guide for primary health care professionals
A summary of the Clinical Practice Guidelines: Depression in adolescents and young adults
Read more on beyondblue website
Compulsions | CRUfAD
CONTACT US URGENT CARE About Us Our Research For Patients For Clinicians Select Page Compulsions OCD Pages 271-276 from the Management of Mental Disorders, published by World Health Organization, Sydney
Read more on CRUfAD – Clinical Research Unit for Anxiety and Depression website
Newer antidepressants for depression in children and adolescents | Cochrane
Depression is common in young people and can contribute to a variety of negative outcomes, such as poor academic functioning, difficulties in peer and family relationships, increases in substance use, and both attempted and completed suicide. This review contained 19 trials (with a total of 3353 participants) testing the effectiveness of newer generation antidepressants (these are antidepressants developed and used since tricyclic antidepressants were developed). These include the well-known selective serotonin reuptake inhibitors that have an impact primarily on the brain chemical called serotonin, as well as several other newer classes of antidepressants now being used, which aim to target noradrenaline and dopamine as well as serotonin and include selective norepinephrine reuptake inhibitors (SNRIs), norepinephrine reuptake inhibitors (NRIs), norepinephrine dopamine reuptake inhibitors (NDRIs), norepinephrine dopamine disinhibitors (NDDIs) and tetracyclic antidepressants (TeCAs)) for the treatment of depression in children and adolescents. Based on 14 of the trials (2490 participants in total), there was evidence that those treated with an antidepressant had lower depression severity scores than those on placebo, however, the size of this difference was small. Based on 17 trials (3229 participants in total), there was evidence of an increased risk (64%) of suicide-related outcomes for those on antidepressants compared with those given placebo. Where rates of adverse events were reported, this was higher for those prescribed an antidepressant. There was no evidence that one particular type of newer generation antidepressant had a larger effect than the others when compared to placebo.
Read more on Cochrane (Australasian Centre) website
